Compare SII & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SII | ARQT |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 3.3B |
| IPO Year | 2011 | 2020 |
| Metric | SII | ARQT |
|---|---|---|
| Price | $146.92 | $22.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $132.00 | $31.86 |
| AVG Volume (30 Days) | 221.6K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $26.22 | $34.46 |
| Revenue Next Year | $11.39 | $29.77 |
| P/E Ratio | $63.42 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $39.33 | $11.86 |
| 52 Week High | $169.63 | $31.77 |
| Indicator | SII | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 35.49 |
| Support Level | $79.37 | $22.56 |
| Resistance Level | $167.47 | $27.26 |
| Average True Range (ATR) | 7.71 | 1.24 |
| MACD | -2.60 | -0.26 |
| Stochastic Oscillator | 7.65 | 2.22 |
Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.